Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
about
Definition of a molecular pathway mediating α-synuclein neurotoxicityRetrograde labeling, transduction, and genetic targeting allow cellular analysis of corticospinal motor neurons: implications in health and diseaseCatecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disordersAlpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivoCofilin 1 activation prevents the defects in axon elongation and guidance induced by extracellular alpha-synucleinα-Synuclein induced toxicity in brain stem serotonin neurons mediated by an AAV vector driven by the tryptophan hydroxylase promoter.Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectorsThe contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's diseaseParkinson's disease: animal models and dopaminergic cell vulnerabilityIntrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degenerationMorphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal systemAxon degeneration and PGC-1α-mediated protection in a zebrafish model of α-synuclein toxicityLack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression.Systemic gene delivery to the central nervous system using Adeno-associated virus.rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons.Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.Alpha-synuclein transfers from neurons to oligodendrocytes.Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injuryTargeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in MouseImpaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons.Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.CD24 expression does not affect dopamine neuronal survival in a mouse model of Parkinson's disease.Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons.Cyclosporin promotes neurorestoration and cell replacement therapy in pre-clinical models of Parkinson's diseaseAnimal models of Parkinson's disease: limits and relevance to neuroprotection studies.Enhancing Transgene Expression from Recombinant AAV8 Vectors in Different Tissues Using Woodchuck Hepatitis Virus Post-Transcriptional Regulatory ElementTRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF.TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicityFunctional Rescue of Dopaminergic Neuron Loss in Parkinson's Disease Mice After Transplantation of Hematopoietic Stem and Progenitor Cells.Caudo-rostral brain spreading of α-synuclein through vagal connectionsα-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease.Rodent models of Parkinson's disease: beyond the motor symptomatologyBrain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunitiesRNA Interference of Human α-Synuclein in Mouse.Lack of spontaneous age-related brain pathology in Octodon degus: a reappraisal of the modelα-Synuclein elevation in human neurodegenerative diseases: experimental, pathogenetic, and therapeutic implications.Neurotrophic molecules in the treatment of neurodegenerative disease with focus on the retina: status and perspectives.Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.
P2860
Q26269832-5BFE0FEB-1C7B-4CCB-B365-EE488CA9FC34Q26823894-57C16394-FCA7-437B-AE62-A542CD0EC915Q26826093-3609A8B0-FD8B-4526-A7F7-F72A270AD734Q27300819-9EAC87F2-1FA0-4D83-B527-F761AB1D6C6FQ27306687-4186FE62-143E-48F4-82CA-238DA1B7CCEBQ27313863-479F8F73-CFF1-49A2-9D1D-C9234C9E51BBQ27318127-03415E51-E219-492B-BC38-F23E65DBAB5CQ28068464-B0E56B62-2A64-40B4-9120-16B050A28684Q28080503-288CB90E-5C74-4F2E-861A-B435C6918FE3Q30373366-9A6426F3-1BED-4EEA-BF0C-5295103C898EQ30446265-A1ACBB95-0C4A-4A9B-8CBF-8C4B0AE760B4Q30577415-9BD3F5C9-C104-4FC5-BFF8-F1045F4C7F5DQ30658867-F3DE1E45-4B28-4583-8ED5-B97FDEC7F571Q33695674-58487FFE-69C2-40FE-B0A7-CDA207E1E91CQ34465572-2ED3A450-BFA2-4522-BC28-CD0556D18B5AQ34503671-F0DEEFCE-2B71-4F2F-BDB5-F03508DDBD5CQ35058359-77F54E98-4B0D-4EFB-8C14-AAE587B01305Q35079415-723FF26E-E650-4113-BD79-31E40B917DCEQ35206648-585ECFC1-B96A-496B-9F38-52EF79E46EB5Q35675406-52B59D8D-B831-4076-A782-60F114FDF287Q35807528-A2D4CE63-D19B-4AAC-A6AF-2515CEFE609EQ35922870-5741564F-F860-4FEF-A6DD-399F8E380E66Q36275740-B535E502-2DF3-426A-89F9-B8EA232235E4Q36293826-92ECFE29-65D0-4033-9129-E4FF334A1970Q36370618-518AD8F1-BEA3-4FCD-9A4D-073B3CB2570EQ36454426-03333C51-8136-443F-9B6C-2F015B1466B2Q36792325-501BF83C-EAA2-42CB-9BA6-AFC5FF9BDA61Q36824652-2CE3AE6E-0579-477A-BC47-E1997B9B98E8Q36835587-D6D317BA-EC38-4CEC-AB0E-9B179EC92318Q37034654-1F6B9AAB-1CD2-403C-B1A9-D922B320F0CFQ37040842-92397427-12BB-4328-BEA5-5DE769726CC0Q37242415-4C51D0FD-0F1A-4D58-B59B-628FA979680EQ37343565-4F62217F-A6E6-4539-A52C-B0CFE98B2B09Q37605018-C2AEEC96-D961-486F-B772-B23C34227E29Q37614503-C578495A-D5BC-45A9-9A23-BB507000B783Q37736494-FEC334DE-792E-47BF-A68F-C81C5A1BE20BQ38040282-0513D5D8-493C-4FDB-AEDC-3412D8BE6344Q38086746-BC916BD3-E184-403C-B2FE-D6C6F3DCFDF6Q38128456-5C82C9AF-FB39-481F-BF2D-E864DBE8BF77Q38607819-4DD79DE3-0C85-4261-BF92-EA3D17ED3A5E
P2860
Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Progressive neurodegenerative ...... in midbrain dopamine neurons.
@ast
Progressive neurodegenerative ...... in midbrain dopamine neurons.
@en
Progressive neurodegenerative ...... in midbrain dopamine neurons.
@nl
type
label
Progressive neurodegenerative ...... in midbrain dopamine neurons.
@ast
Progressive neurodegenerative ...... in midbrain dopamine neurons.
@en
Progressive neurodegenerative ...... in midbrain dopamine neurons.
@nl
prefLabel
Progressive neurodegenerative ...... in midbrain dopamine neurons.
@ast
Progressive neurodegenerative ...... in midbrain dopamine neurons.
@en
Progressive neurodegenerative ...... in midbrain dopamine neurons.
@nl
P2093
P921
P1476
Progressive neurodegenerative ...... in midbrain dopamine neurons.
@en
P2093
B Mattsson
M Decressac
M Lundblad
P304
P356
10.1016/J.NBD.2011.12.013
P577
2011-12-11T00:00:00Z